Dermatologic Adverse Events from Cancer Treatments

Abstract

The incidences of adverse events to cancer treatments have increased as new treatments are being developed. Dermatologic adverse events (dAEs) strongly impact patients’ quality of life (QoL). Severe dAEs can result in dose reduction or discontinuation, which may compromise clinical outcomes and even lead to life-threatening conditions. Prevention, early diagnosis, and proper management of dAEs are crucial for optimizing anticancer response and maintaining QoL. This chapter addresses dAEs induced by cytotoxic and targeted therapies, radiotherapy, stem cell transplantation, immunotherapies, and CAR-T cell therapy. Proposed underling mechanisms and recommended treatment approaches for these dAEs are presented.